European Medicines Agency

The European Medicines Agency (EMA), the European Union’s drug-regulating body, helped widen the clinical question being asked about psilocybin: from whether it might ease distress in patients facing life-changing diagnoses to whether it could treat depression more broadly. Its intervention gave early findings a new regulatory direction, while underscoring that promising results were a reason to test further, not proof that the treatment was established.

A regulatory reframing

In 2016, researchers approached the European Medicines Agency seeking permission to study psilocybin for anxiety and depression among patients with life-changing diagnoses. The agency noted a practical obstacle: existential distress was not an official DSM diagnosis, so national health services would not cover it. But rather than treating that mismatch as the end of the inquiry, the EMA pointed to a possible signal for depression and proposed a large, multisite trial to investigate that broader indication.

The exchange altered the scale and framing of the research question. Researchers had focused on seriously ill or dying patients partly because they thought it would be easier to obtain permission to study a controlled substance in that population. The EMA’s response suggested that evidence gathered in such settings might warrant testing a wider therapeutic claim. It did not itself authorize a treatment or establish that psilocybin worked for depression; it urged researchers to pursue the question with a more substantial study.

Evidence behind the proposal

The European Medicines Agency was responding both to results from cancer-patient studies at New York University and Johns Hopkins and to a small feasibility study at Imperial College London. Directed by Robin Carhart-Harris in David Nutt’s lab, that study enrolled six men and six women with treatment-resistant depression, meaning that each had already tried at least two treatments without success. There was no control group, and participants knew they were receiving psilocybin.

After a week, all twelve volunteers had improved symptoms, and two-thirds were depression-free; for some, this was the first such relief in years. Seven still showed substantial benefit at three months. The study then expanded to twenty participants: at six months, six remained in remission, while the others had relapsed to varying degrees. The results were preliminary, but the treatment was well tolerated in this group, with no adverse events reported, and most participants experienced marked, rapid benefits. The EMA considered the findings sufficient to suggest a much larger trial of psilocybin for treatment-resistant depression.

The scale of the proposed question mattered. The book places treatment-resistant depression in Europe at more than 800,000 people, within a broader population of roughly 40 million Europeans with depressive disorders. The EMA’s recommendation thus connected a small, uncontrolled feasibility study to a potential research program addressing a much larger unmet need, without treating the initial results as conclusive.

Significance and limits

The EMA’s response belongs to a wider challenge facing psychedelic research: conventional drug testing seeks to isolate a substance’s effect, while a psychedelic session combines the drug with therapeutic support, participants’ expectations, and the conditions in which it is administered. Those features complicate blinding and make it difficult to separate pharmacological action from set and setting. A call for a larger trial therefore did not remove the methodological problem; it raised the prospect of testing the treatment on a scale that could better examine its promise.

The agency’s role in the account is consequential but carefully bounded. It recognized a signal in early findings and pressed researchers to address depression through larger studies, helping shift attention beyond the original focus on distress associated with severe illness. That stance made the European Medicines Agency an important participant in the research revival—not as an endorser of settled efficacy, but as a regulator encouraging a broader and more demanding test of what the preliminary evidence might mean.